Venlafaxine: Acute and chronic effects on 5-hydroxytryptamine levels in rat brain in vivo

European Journal of Pharmacology

Volumn 372, Issue 1, 1999, Pages 17-24

  Gur, Eitan ^a   Dremencov, Eliyahu ^a   Lerer, Bernard ^a   Newman, Michael E ^a  

^a HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

Author keywords

5 HT (5 hydroxytryptamine, serotonin); 5 HT(1A) receptor; Antidepressant; Cortex; Hippocampus; Microdialysis; Venlafaxine

Indexed keywords

2 DIPROPYLAMINO 8 HYDROXYTETRALIN; ANTIDEPRESSANT AGENT; AUTORECEPTOR; CITALOPRAM; NORADRENALIN UPTAKE INHIBITOR; PINDOLOL; SEROTONIN; SEROTONIN 1A RECEPTOR; SEROTONIN UPTAKE INHIBITOR; VENLAFAXINE;

ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; DRUG POTENTIATION; FRONTAL CORTEX; HIPPOCAMPUS; INTRAPERITONEAL DRUG ADMINISTRATION; LONG TERM EXPOSURE; MALE; MICRODIALYSIS; NONHUMAN; PRIORITY JOURNAL; RAT; SEROTONIN BRAIN LEVEL; SUBCUTANEOUS DRUG ADMINISTRATION;

8-HYDROXY-2-(DI-N-PROPYLAMINO)TETRALIN; ANALYSIS OF VARIANCE; ANIMALS; BRAIN; CYCLOHEXANOLS; DOSE-RESPONSE RELATIONSHIP, DRUG; HIPPOCAMPUS; INJECTIONS, INTRAPERITONEAL; MALE; PINDOLOL; PREFRONTAL CORTEX; RATS; SEROTONIN; SEROTONIN AGONISTS; SEROTONIN ANTAGONISTS; SEROTONIN UPTAKE INHIBITORS;

EID: 0032894207     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0014-2999(99)00164-8     Document Type: Article

References (49)

1. 1A receptor antagonist (S)-UH-301 augments the increase in extracellular concentrations of 5-HT in the frontal cortex produced by both acute and chronic treatment with citalopram. Naunyn-Schmiedeberg's Arch. Pharmacol. 353:1996;630-640.
2. Artigas F., Perez V., Alvarez E. Pindolol induces a rapid improvement of depressed patients treated with serotonin reuptake inhibitors. Arch. Gen. Psychiatry. 51:1994;248-251.
3. 1B receptors. Neuropharmacology. 35:1996;213-222.
4. Auerbach S.B., Hjorth S. Effect of chronic administration of the selective serotonin uptake inhibitor citalopram on extracellular 5-HT and apparent autoreceptor sensitivity in rat forebrain in vivo. Naunyn-Schmiedeberg's Arch. Pharmacol. 352:1995;597-606.
5. Beique J.-C., Lavoie N., de Montigny C., Debonnel G. Affinities of venlafaxine and various reuptake inhibitors for the serotonin and norepinephrine transporters. Eur. J. Pharmacol. 349:1998;129-132.
6. Beique J.-C., de Montigny C., Blier P., Debonnel G. Blockade of 5-hydroxytryptamine and noradrenaline uptake by venlafaxine: a comparative study with paroxetine and desipramine. Br. J. Pharmacol. 125:1998;526-532.
7. Bel N., Artigas F. Fluvoxamine preferentially increases extracellular 5-hydroxytryptamine in the raphe nuclei: an in vivo microdialysis study. Eur. J. Pharmacol. 229:1992;101-103.
8. Bel N., Artigas F. Chronic treatment with fluvoxamine increases extracellular serotonin in frontal cortex but not in raphe nuclei. Synapse. 15:1993;243-245.
9. Bel N., Artigas F. In vivo effects of the simultaneous blockade of serotonin and norepinephrine transporters on serotonergic function: microdialysis studies. J. Pharmacol. Exp. Ther. 278:1996;1064-1072.
10. Blier P., de Montigny C. Current advances and trends in the treatment of depression. Trends Pharmacol. Sci. 15:1994;220-226.
11. Blier P., Bergeron R. Effectiveness of pindolol with selected antidepressant drugs in the treatment of major depression. J. Clin. Psychopharmacol. 15:1995;217-222.
12. 1A receptors induces rapid antidepressant response. Neuropsychopharmacology. 16:1997;333-338.
13. Bolden-Watson C., Richelson E. Blockade by newly-developed antidepressants of biogenic amine uptake into rat brain synaptosomes. Life Sci. 52:1993;1023-1029.
14. Bosker F.J., Donker M.G., Klompmakers A.A., Kurata K., Westenberg H.G.M. 5-hydroxytryptamine release in dorsal hippocampus of freely moving rats: modulation by pindolol. Prog. Neuro-Psychopharmacol. Biol. Psychiatry. 18:1994;765-778.
15. Bosker F.J., Klompmakers A.A., Westenberg H.G.M. Effects of single and repeated oral administration of fluvoxamine on extracellular serotonin in the median raphe nucleus and dorsal hippocampus of the rat. Neuropharmacology. 34:1995;501-508.
16. 1B receptors, as measured by in vivo microdialysis in dorsal hippocampus of conscious rats. Psychopharmacology. 117:1995;358-363.
17. 1A autoreceptor in vivo. Br. J. Pharmacol. 124:1998;206-212.
18. 1A receptors. Neurochem. Res. 21:1996;557-562.
19. Engleman E.A., Perry K.W., Mayle D.A., Wong D.T. Simultaneous increases of extracellular monoamines in microdialysates from hypothalamus of conscious rats by duloxetine, a dual serotonin and norepinephrine uptake inhibitor. Neuropsychopharmacology. 12:1995;287-295.
20. Engleman E.A., Robertson D.W., Thompson D.C., Perry K.W., Wong D.T. Antagonism of serotonin 5-HT1A receptors potentiates the increases in extracellular monoamines induced by duloxetine in rat hypothalamus. J. Neurochem. 66:1996;599-603.
21. Fuller R.W. Uptake inhibitors increase extracellular serotonin concentration measured by brain microdialysis. Life Sci. 55:1994;163-167.
22. 1A autoreceptors and noradrenergic mechanisms. Psychopharmacology. 130:1997;261-268.
23. Gundlah C., Hjorth S., Auerbach S.B. Autoreceptor antagonists enhance the effect of the reuptake inhibitor citalopram on extracellular 5-HT: this effect persists after repeated citalopram treatment. Neuropharmacology. 36:1997;475-482.
24. Gur E., Lerer B., Newman M.E. Chronic electroconvulsive shock and 5-HT autoreceptor activity in rat brain: an in vivo microdialysis study. J. Neural Transm. 104:1997;795-804.
25. Gur E., Lerer B., Newman M.E. Chronic clomipramine and triiodothyronine increase 5-HT levels in rat frontal cortex in vivo: relationship to 5-HT autoreceptor activity. J. Pharmacol. Exp. Ther. 288:1999;81-87.
26. Hjorth S. (-)Pindolol, but not buspirone, potentiates the citalopram-induced rise in extracellular 5-hydroxytryptamine. Eur. J. Pharmacol. 303:1996;183-186.
27. 1A autoreceptor desensitization following chronic citalopram treatment, as determined by in vivo microdialysis. Neuropharmacology. 33:1994;331-334.
28. 3H ]imipramine localization and relationship to serotonin transport J. Pharmacol. Exp. Ther. 252:1990;410-418.
29. 1A receptors. Eur. J. Pharmacol. 260:1994;243-246.
30. Invernizzi R., Bramante M., Samanin R. Extracellular concentrations of serotonin in the dorsal hippocampus after acute and chronic treatment with citalopram. Brain Res. 696:1995;62-66.
31. 1A receptors in the effects of acute and chronic fluoxetine on extracellular serotonin in the frontal cortex. Pharmacol. Biochem. Behav. 54:1996;143-147.
32. 1A receptor antagonists on citalopram-induced increase in extracellular serotonin in the frontal cortex, striatum and dorsal hippocampus. Neuropharmacology. 36:1997;467-473.
33. Kasamo K., Blier P., de Montigny C. Blockade of the serotonin and norepinephrine uptake processes by duloxetine: in vitro and in vivo studies in the rat brain. J. Pharmacol. Exp. Ther. 277:1996;278-286.
34. Kihara T., Ikeda M. Effects of duloxetine, a new serotonin and norepinephrine uptake inhibitor, on extracellular monoamine levels in rat frontal cortex. J. Pharmacol. Exp. Ther. 272:1995;177-183.
35. Kreiss D.S., Lucki I. Effects of acute and repeated administration of antidepressant drugs on extracellular levels of 5-HT measured in vivo. J. Pharmacol. Exp. Ther. 274:1995;866-876.
36. Maione S., Palazzo E., Pallotta M., Leyva J., Berrino L., Rossi F. Effects of imipramine on raphe nuclei and prefrontal cortex extracellular serotonin levels in the rat. Psychopharmacology. 134:1997;401-405.
37. Malagie I., Trillat A.-C., Jacquot S.C., Gardier A.M. Effects of acute fluoxetine on extracellular serotonin levels in the raphe: an in vivo microdialysis study. Eur. J. Pharmacol. 286:1995;213-217.
38. Moret C., Briley M. Effects of acute and repeated administration of citalopram on extracellular levels of serotonin in rat brain. Eur. J. Pharmacol. 295:1996;189-197.
39. Moret C., Briley M. Effects of milnacipran and pindolol on extracellular noradrenaline and serotonin levels in guinea-pig hypothalamus. J. Neurochem. 69:1997;815-822.
40. Muth E.A., Haskins J.T., Moyer J.A., Husbands G.E.M., Nielsen S.T., Sigg E.B. Antidepressant biochemical profile of the novel bicyclic compound Wy-45,030, an ethyl cyclohexanol derivative. Biochem. Pharmacol. 35:1986;4493-4497.
41. 1A) receptors. Neuropsychopharmacology. 18:1998;395-398.
42. Owens M.J., Morgan W.N., Plott S.J., Nemeroff C.B. Neurotransmitter receptor and transporter binding profile of antidepressants and their metabolites. J. Pharmacol. Exp. Ther. 283:1997;1305-1322.
43. 1B receptors in antidepressant drug actions in the mouse forced swimming test. Eur. J. Pharmacol. 318:1996;213-220.
44. Redrobe J.P., Bourin M., Colombel M.C., Baker G.B. Dose-dependent noradrenergic and serotonergic properties of venlafaxine in animal models indicative of antidepressant activity. Psychopharmacology. 138:1998;1-8.
45. 1A antagonist WAY-100635 selectively potentiates the presynaptic effects of serotonergic antidepressants in rat brain. Neurosci. Lett. 219:1996;123-126.
46. 1A receptors: in vivo microdialysis and electrophysiological studies in the rat brain. Neuropsychopharmacology. 15:1996;349-360.
47. Rutter J.J., Gundlah C., Auerbach S.B. Increase in extracellular serotonin produced by uptake inhibitors is enhanced after chronic treatment with fluoxetine. Neurosci. Lett. 171:1994;183-186.
48. Sleight A.J., Smith R.J., Marsden C.A., Palfreyman M.G. The effects of chronic treatment with amitriptyline and MDL 72394 on the control of 5-HT release in vivo. Neuropharmacology. 28:1989;477-480.
49. Tanda G., Frau R., Di Chiara G. Chronic desipramine and fluoxetine differentially affect extracellular dopamine in the rat prefrontal cortex. Psychopharmacology. 127:1996;83-87.